A new study led by researchers at NYU Langone Health has revealed that a special group of cells found in mouse intestines ...

UK biotech Epsilogen has acquired US-based antibody developer TigaTx in a deal that collates work from the two companies’ ...

UK biotech Epsilogen has bought US-based TigaTx, pooling their resources to create what it says will be a leader in ...

The treatment of asthma and allergic rhinitis using unique, humanized anti-IgE monoclonal antibodies with very particular binding specificities is now supported by the results of multiple phase II ...

Epsilogen completes acquisition of TigaTx to create world’s leading pan-isotype cancer antibody company: London Tuesday, April 8, 2025, 10:00 Hrs [IST] Epsilogen, the global lea ...

Study reveals how a new IgE antibody therapy reactivates immune cells, offering a promising approach to fighting ovarian ...

Research has shed light on how a new type of antibody treatment reactivates patients' immune cells to fight ovarian cancer.

Symptoms of seasonal allergies and the common cold can overlap. Learn how to tell them apart so you can get the treatment you ...

With an arsenal of antibody assets based on IgE, IgA, and IgG, the newly combined company has opportunities across cancer indications.

U.K.-based Epsilogen has bought Boston biotech TigaTx with the aim of creating “the world’s leading pan-isotype cancer ...

Epsilogen, the global leader in the development of immunoglobulin E (IgE) antibody therapeutics, today announces that it has completed the acquisition of TigaTx, Inc., a biotechnology company ...